文献速递肿瘤 PET/CT

FAPI PET/CT在胆管癌与胰腺癌中的价值:最新进展

The Value of FAPI PET/CT in Cholangiocarcinoma and Pancreatic Cancer: An Update.
PubMed 文献 · Semin Nucl Med · 2025-07-16

本文综述了FAPI PET/CT在胰腺癌和胆管癌中的临床应用证据。近期研究显示,FAPI PET/CT在检测原发肿瘤、淋巴结受累和远处转移方面灵敏度优于增强CT和18F-FDG PET/CT,尤其对肝转移因生理背景摄取低而更具优势,并可影响TNM分期及治疗决策。早期证据提示其具有预后评估潜力,但数据有限,且在肝硬化、胰腺炎、原发性硬化性胆管炎等纤维化和炎症过程中可能出现假阳性。

要点

  • FAPI PET/CT检测胆管癌和胰腺癌原发灶、淋巴结及远处转移的灵敏度优于增强CT和18F-FDG PET/CT。
  • FAPI PET/CT可影响TNM分期并改变治疗决策。
  • 早期证据提示FAPI PET/CT在肿瘤分级、疗效评估和生存结局方面有预后潜力,但数据有限。

核心结论

  • FAPI PET/CT在胆管癌和胰腺癌中显示出优于增强CT和18F-FDG PET/CT的灵敏度,并可影响TNM分期和治疗决策;早期证据提示其预后潜力,但数据有限,且在纤维化和炎症过程中可能出现假阳性。

研究设计与样本

  • 本文为综述,汇总FAPI PET/CT在胰腺癌和胆管癌中的当前临床证据,聚焦诊断性能、预后相关性、治疗意义和潜在陷阱。

主要发现

  • 近期研究显示,FAPI PET/CT在胆管癌和胰腺癌中检测原发肿瘤、淋巴结受累和远处转移的灵敏度优于增强CT和18F-FDG PET/CT,尤其因生理背景摄取低而对肝转移更具优势。
  • FAPI PET/CT已被证明可影响TNM分期,并随后改变治疗决策。
  • 早期证据提示FAPI PET/CT在肿瘤分级、疗效评估和生存结局方面具有预后潜力,但数据仍然有限。
  • FAPI PET/CT在肝硬化、胰腺炎或原发性硬化性胆管炎等纤维化和炎症过程中可能出现假阳性。

局限性

  • 早期证据提示FAPI PET/CT在肿瘤分级、疗效评估和生存结局方面具有预后潜力,但数据仍然有限。
  • FAPI PET/CT在肝硬化、胰腺炎或原发性硬化性胆管炎等纤维化和炎症过程中可能出现假阳性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To date, contrast-enhanced CT (ceCT), magnetic resonance imaging (MRI), and, in selected cases, 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) are the current standard imaging modalities for staging of pancreatic cancer and cholangiocarcinoma. Fibroblast activation protein alpha (FAP) has gained interest as a promising molecular imaging target, particularly in tumors with a pronounced desmoplastic reaction such as pancreatic cancer and cholangiocarcinoma. Radiolabeled FAP inhibitors (FAPIs) enable noninvasive visualization of cancer using PET/CT. Recent studies have demonstrated that FAPI PET/CT provides superior sensitivity compared to ceCT and 18F-FDG PET/CT in cholangiocarcinoma and pancreatic cancer for detecting primary tumors, lymph node involvement, and distant metastases, particularly in hepatic metastases due to low physiological background uptake. Furthermore, FAPI PET/CT has been shown to affect TNM staging and subsequently alter treatment-decision making. Beyond staging, early evidence suggests a prognostic potential of FAPI PET/CT in tumor grading, therapy response assessment, and survival outcomes, although data remain limited. On the other hand, FAPI PET/CT comes with limitations, particularly in the context of fibrotic and inflammatory processes such as liver cirrhosis, pancreatitis, or primary sclerosing cholangitis, which may result in false-positive findings. This review summarizes the current clinical evidence for FAPI PET/CT in pancreatic cancer and cholangiocarcinoma, with a focus on diagnostic performance, prognostic relevance, therapeutic implications, and potential pitfalls.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pabst KM, Fendler WP, Jochheim LS, et al. The Value of FAPI PET/CT in Cholangiocarcinoma and Pancreatic Cancer: An Update. Semin Nucl Med. 2025. PMID: 40675899. doi:10.1053/j.semnuclmed.2025.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。